Who are AI browsers for?
OpenAI launched an AI-powered browser this week, but it feels like it offers a slight efficiency gain at best.
Equity
Why Deloitte is betting big on AI despite a $10M refund
AI companies are making their much-anticipated enterprise plays, but the results are wildly inconsistent. Just this week, Deloitte announced it’s rolling out Anthropic’s Claude to all 500,000 employees. On the very same day, the Australian government forced Deloitte to refund a contract because their AI-generated report was riddled with fake citations. It’s a perfect snapshot […]
A break down of the H-1B changes — and why more changes could come
Jeremy Neufeld, the director of immigration policy at the Institute for Progress, comes on Equity to talk H-1B changes.
California’s new AI safety law shows regulation and innovation don’t have to clash
“Are bills like SB 53 the thing that will stop us from beating China? No,” said Adam Billen, vice president of public policy at youth-led advocacy group Encode AI. “I think it is just genuinely intellectually dishonest to say that that is the thing that will stop us in the race.”
California’s new AI safety law shows regulation and innovation don’t have to clash
“Are bills like SB 53 the thing that will stop us from beating China? No,” said Adam Billen, vice president of public policy at youth-led advocacy group Encode AI. “I think it is just genuinely intellectually dishonest to say that that is the thing that will stop us in the race.”
Why California’s SB 53 might provide a meaningful check on big AI companies
Equity debates California’s new AI safety bill and why it has a better shot at becoming law.
Karen Hao on the Empire of AI, AGI evangelists, and the cost of belief
OpenAI’s rise isn’t just a business story — it’s an ideological one. On Equity, Karen Hao, author of Empire AI, explores how the cult of AGI has fueled a billion-dollar race, justified massive spending on compute and data, and blurred the line between mission and profit.
Mark Cuban’s war on America’s $5 trillion healthcare machine: ‘They can’t react as quickly’
Cuban said drug prices are opaque by design. He launched Cost Plus Drugs in 2022 to pull back the curtain on drug pricing, bring down costs to the average consumer, and disrupt the traditional pharmacy industry.